May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Circulating Hematopoietic Stem Cells Control the Progression of Choroidal Neovascularization in Age-Related Macular Degeneration
Author Affiliations & Notes
  • Y. Yodoi
    Ophthalmology, Kyoto University, Kyoto, Japan
  • A. Otani
    Ophthalmology, Kyoto University, Kyoto, Japan
  • M. Sasahara
    Ophthalmology, Kyoto University, Kyoto, Japan
  • T. Kameda
    Ophthalmology, Kyoto University, Kyoto, Japan
  • H. Zou
    Ophthalmology, Kyoto University, Kyoto, Japan
  • N. Yoshimura
    Ophthalmology, Kyoto University, Kyoto, Japan
  • Footnotes
    Commercial Relationships Y. Yodoi, None; A. Otani, None; M. Sasahara, None; T. Kameda, None; H. Zou, None; N. Yoshimura, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4091. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Yodoi, A. Otani, M. Sasahara, T. Kameda, H. Zou, N. Yoshimura; Circulating Hematopoietic Stem Cells Control the Progression of Choroidal Neovascularization in Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4091.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Neovascular age-related macular degeneration (AMD) is a leading cause of irreversible blindness in developed countries. The mechanism and the factors that influence choroidal neovascularization (CNV) have not been fully understood. Recently, hematopoietic stem cells (HSCs) including endothelial progenitor cells (EPCs) have been shown to contribute to experimental CNV. However, the potential role of these cells remains unclear. The purpose of this study is to investigate the potential role of circulating HSCs/EPCs in the progression of CNV.

Methods:: The numbers of HSCs/EPCs in the peripheral blood of neovascular AMD patients (n=81), age matched controls (n=21) and young healthy volunteers (n=10) were analyzed using flow cytometry. We also measured the functions of EPCs using colony forming units of endothelial cells (CFU-EC) and the migration activities of EPCs in ex vivo culture system. CNV activity was judged by the period from the last sign of progression. CNV severity was judged by CNV size and laterality of CNV.

Results:: The number of circulating HSCs/EPCs were increased with the activity of CNV (CD34+HSCs; control: 3.8±0.4cells/µl, stable AMD group: 4.0±0.2cells/µl, active AMD group: 5.3±0.5 cells/µl, control vs. active P=0.02, stable vs. active P=0.01) but not related to the severity of CNV. In contrast, the functions of EPCs did not change with activity of CNV but significantly decreased in severer CNV cases (CFU-EC; large CNV: 21.5±4.4 vs. small CNV: 37.3±6.3, P=0.02, bilateral CNV: 18.8±4.8 vs. unilateral CNV: 33.2±5.0, P=0.02).

Conclusions:: Bone marrow derived cells may have an important role in the formation and progression of CNV in AMD patients. Controlling the circulating HSCs/EPCs may be a new therapeutic strategy for preventing progression of CNV.

Keywords: age-related macular degeneration • choroid: neovascularization • flow cytometry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×